[
  {
    "ts": null,
    "headline": "Wall Street Lunch: Qualcomm Enters Into AI Accelerator Market To Take On Nvidia, AMD",
    "summary": "Qualcomm (QCOM) announced its entry into the artificial intelligence accelerator market, as it looks to take on Nvidia (NVDA) and AMD (AMD).",
    "url": "https://finnhub.io/api/news?id=a0c1d53d221737afcab0946166b8f491279b1eb6953580cddcefc87455473ed3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761574823,
      "headline": "Wall Street Lunch: Qualcomm Enters Into AI Accelerator Market To Take On Nvidia, AMD",
      "id": 137230710,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202019918/image_1202019918.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Qualcomm (QCOM) announced its entry into the artificial intelligence accelerator market, as it looks to take on Nvidia (NVDA) and AMD (AMD).",
      "url": "https://finnhub.io/api/news?id=a0c1d53d221737afcab0946166b8f491279b1eb6953580cddcefc87455473ed3"
    }
  },
  {
    "ts": null,
    "headline": "Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)",
    "summary": "Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), r",
    "url": "https://finnhub.io/api/news?id=534aebe19b3ae255703a9366cfcb02c376f5a5fe0868cce59b621db8c7f867ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761564600,
      "headline": "Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)",
      "id": 137228956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), r",
      "url": "https://finnhub.io/api/news?id=534aebe19b3ae255703a9366cfcb02c376f5a5fe0868cce59b621db8c7f867ba"
    }
  },
  {
    "ts": null,
    "headline": "OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics",
    "summary": "DALLAS, October 27, 2025--OncoNano Medicine, Inc. (\"OncoNano\") announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, in patients with advanced solid tumors and lymphomas. The findings were shared during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, M",
    "url": "https://finnhub.io/api/news?id=6968c853d8730fa4438258de9267643bd4687b50e6a99bea91c38034c1dcd5ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761562800,
      "headline": "OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics",
      "id": 137228957,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "DALLAS, October 27, 2025--OncoNano Medicine, Inc. (\"OncoNano\") announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, in patients with advanced solid tumors and lymphomas. The findings were shared during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, M",
      "url": "https://finnhub.io/api/news?id=6968c853d8730fa4438258de9267643bd4687b50e6a99bea91c38034c1dcd5ba"
    }
  },
  {
    "ts": null,
    "headline": "A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo",
    "summary": "Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the European Medicines Agency’s committee issued a positive opinion for Libtayo as an adjuvant treatment for certain skin cancer patients. See our latest analysis for Regeneron Pharmaceuticals. This regulatory progress adds to a busy stretch for Regeneron, which recently presented at the ESMO Congress and has continued ramping up share repurchases according to major...",
    "url": "https://finnhub.io/api/news?id=6fa9593ebc0337e9f115564613c3e67f0b3cf73ebca4b25a606df44a8c6a8957",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761538636,
      "headline": "A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo",
      "id": 137217202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the European Medicines Agency’s committee issued a positive opinion for Libtayo as an adjuvant treatment for certain skin cancer patients. See our latest analysis for Regeneron Pharmaceuticals. This regulatory progress adds to a busy stretch for Regeneron, which recently presented at the ESMO Congress and has continued ramping up share repurchases according to major...",
      "url": "https://finnhub.io/api/news?id=6fa9593ebc0337e9f115564613c3e67f0b3cf73ebca4b25a606df44a8c6a8957"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Earnings: What To Look For From REGN",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.",
    "url": "https://finnhub.io/api/news?id=b8d2519fc0f402ecbff879fb8d0c55f990d90a680fb30afca8df12f3eea7674a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761534806,
      "headline": "Regeneron Earnings: What To Look For From REGN",
      "id": 137217203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.",
      "url": "https://finnhub.io/api/news?id=b8d2519fc0f402ecbff879fb8d0c55f990d90a680fb30afca8df12f3eea7674a"
    }
  }
]